547 evidence-based articles, checked against primary sources.

How common is thyroid disease, and how much more often does it affect women? A primary-sourced rundown of hypothyroidism and hyperthyroidism prevalence, the undiagnosed gap, leading causes, and age patterns.

Persistent tiredness in women has many possible causes, from poor sleep and perimenopause to iron deficiency, thyroid problems, and sleep apnea. Here are the red flags to act on and the simple blood tests a clinician can order.

Weight that rises without a clear change in eating or exercise has many possible explanations, from perimenopause and an underactive thyroid to medications and fluid retention. Here is how to tell what is worth checking, and when the change needs a doctor sooner rather than later.

Breast pain is extremely common and rarely a sign of cancer. Here are the usual causes — hormonal, perimenopausal, cysts, medications, and muscle or chest-wall pain — plus the warning signs that need prompt evaluation.

Most HRT appointments are 10 to 15 minutes. This guide gives you seven question sets to take in — candidacy, type and route, your real numbers, what to expect, follow-up, vaginal symptoms, and cost — plus the red flags in a clinician's answer that mean you should get a second opinion.

Not all at-home thyroid tests are equal. Learn which markers matter (TSH, free T4, free T3, TPO antibodies), why a CLIA-certified lab and physician review count, when a clinician-ordered panel is better, and how thyroid symptoms overlap with menopause.

Honest, broad cost ranges for menopause care across countries and insurance situations — from clinician visits and HRT to testing, telehealth, and supplements — with realistic ways to lower your bill.

DEXA scans measure bone density at the hip and spine and give a T-score that can diagnose osteoporosis. At-home bone tests measure turnover markers or use heel ultrasound and cannot. Here is how they compare on what they measure, diagnosis, usefulness, and cost.

Weigh the real costs and trade-offs of menopause telehealth against in-person and primary care — from subscription and per-visit fees to labs, prescriptions, insurance, and continuity — so you can decide whether online menopause care is worth it for you.

Mail-in kits promise answers about menopause, but after 45 the diagnosis comes from your symptoms, not a hormone level. Here's what at-home tests measure, what they miss, and when clinician-ordered bloodwork is genuinely worth doing.

At-home hormone tests range from about $30 for a single marker to $350 or more for a comprehensive panel, plus monthly subscription options. Here is what each tier includes, what is usually left out, and why the hidden cost of interpretation and follow-up matters more than the sticker price.

Estrogen-only HRT is generally for women who've had a hysterectomy, while those who still have a uterus usually need combined HRT to protect the womb lining. Here's the plain-language difference, and what cyclical vs. continuous means for bleeding.

This is not a "we tested the kits" ranking and gives no brand scores. It is a plain-language guide to the eight criteria — from which biomarkers are measured to whether a CLIA-certified lab runs your sample — that separate a useful at-home hormone test from a slick label.

Pills, patches, and gels or sprays all deliver systemic estrogen for menopause — but they differ in absorption, blood-clot risk, skin reactions, convenience, and cost. Here's how the routes compare and who each tends to suit.

HRT is the most effective option for menopausal hot flashes, and specific SSRIs and SNRIs are an evidence-based non-hormonal alternative — especially when hormones aren't suitable or depression is also present. A plain-language comparison of both.

Fezolinetant (Veozah) and HRT both calm menopausal hot flashes, but they work differently and address different symptoms. Here's an evidence-based, no-hype comparison to bring to your clinician.

In November 2025 the FDA began stripping the boxed warning from menopausal hormone therapy labels, and the first approved label changes landed in February 2026. It is a real regulatory shift — but it is a change to a label, not a change to your body. Here is what the warning said, why it was there, what the evidence actually shows, and what still deserves a careful conversation with a clinician.

A calm, myth-by-myth look at hormone therapy: what the WHI study really found, how later re-analysis changed the picture, and why suitability is a personal conversation with your clinician.